Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Cash Flows From Operating Activities
Net loss	$ (35,053)	$ (14,020)
Adjustments to reconcile net (loss)/income to net cash and cash equivalents (used in)/provided by operating activities:
Stock-based compensation	6,993	4,713
Deferred taxes	(11,378)	(6,676)
Depreciation and amortization	28,731	22,222
Non-cash interest	1,969	1,141
Contingent consideration fair value adjustment	(342)	0
Asset impairment charges	575	0
Gain on sale of ANDAs	(750)	0
Changes in operating assets and liabilities:
Accounts receivable, net	(21,884)	3,145
Inventories, net	(10,852)	2,823
Prepaid expenses and other current assets	1,563	1,202
Accounts payable	4,047	1,688
Accrued royalties	70	(1,719)
Current income taxes payable, net	1,654	(6,281)
Accrued government rebates	3,948	914
Returned goods reserve	(903)	4,754
Accrued expenses, accrued compensation, and other	1,186	7,003
Net Cash and Cash Equivalents (Used in)/Provided by Operating Activities	(30,426)	20,909
Cash Flows From Investing Activities
Acquisition of Novitium Pharma LLC, net of cash acquired	(33)	0
Acquisition of product rights, IPR&D, and other related assets	(229)	(21,057)
Acquisition of property and equipment, net	(3,270)	(1,630)
Proceeds from the sale of long-lived assets	750	0
Net Cash and Cash Equivalents Used in Investing Activities	(2,782)	(22,687)
Cash Flows From Financing Activities
Payments on borrowings under credit agreements	(1,500)	(5,206)
Borrowings under Revolver agreement	0	24,000
Series A convertible preferred stock dividends paid	(812)	0
Proceeds from stock option exercises and ESPP purchases	206	336
Payments of debt issuance costs	0	(141)
Treasury stock purchases for restricted stock vests	(1,601)	(816)
Net Cash and Cash Equivalents (Used in)/Provided by Financing Activities	(3,707)	18,173
Net Change in Cash and Cash Equivalents	(36,915)	16,395
Cash and cash equivalents, beginning of period	105,301	12,867
Cash and cash equivalents, end of period	68,386	29,262
Reconciliation of cash, cash equivalents, and restricted cash, beginning of period
Cash and cash equivalents	100,300	7,864
Restricted cash	5,001	5,003
Cash and cash equivalents, beginning of period	105,301	12,867
Reconciliation of cash, cash equivalents, and restricted cash, end of period
Cash and cash equivalents	63,385	24,261
Restricted cash	5,001	5,001
Cash and cash equivalents, end of period	68,386	29,262
Supplemental disclosure for cash flow information:
Cash paid for interest, net of amounts capitalized	11,400	3,953
Cash paid for income taxes	124	8,360
Supplemental non-cash investing and financing activities:
Debt issuance costs in accrued expenses	0	81
Property and equipment purchased and included in accounts payable	$ 779	$ 119